| Literature DB >> 30652743 |
Piotr Węgrzyn1, Grzegorz Lis2, Paweł Rudzinski1, Jacek Piatek1, Grazyna Pyka-Fosciak2, Ryszard Korbut3, Boguslaw Kapelak1, Krzysztof Bartus1, Radoslaw Litwinowicz1.
Abstract
OBJECTIVE: The aim of this study was to compare the efficacy of two different papaverine concentrations (0.5 mg/ml and 2 mg/ml) for vasospasm prevention and their impact on endothelium integrity.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30652743 PMCID: PMC6326436 DOI: 10.21470/1678-9741-2018-0139
Source DB: PubMed Journal: Braz J Cardiovasc Surg ISSN: 0102-7638
Patients’ clinical characteristics.
| Patients’ characteristics | Average ± SD or n (%) | |
|---|---|---|
| Age (years) | 67.5±4.95 | |
| Systolic blood pressure (mmHg) | 135±7.82 | |
| Diastolic blood pressure (mmHg) | 86.5±4.84 | |
| BMI (kg/m²) | 27.51±1.18 | |
| CK-MB | 38.1±32.56 | |
| Hospitalization (days) | 8.8±1.93 | |
| ICU (days) | 2.1±1.2 | |
| Post-surgical drainage (ml) | 779±469.88 | |
| Blood unit transfusion (number) | 2.3±1.7 | |
| Gender | Male | 1 (10%) |
| Female | 9 (90%) | |
| CCS scale | II | 2 (20%) |
| III | 7 (70%) | |
| IV | 1 (10%) | |
| Smoking | 5 (50%) | |
| Arterial hypertension | 8 (80%) | |
| Diabetes | 7 (70%) | |
| Myocardial infarction | 2 (20%) | |
| Atrial fibrillation | 7 (70%) | |
| Pressor drugs | 10 (100%) | |
| Rethoracotomy | 1 (10%) | |
BMI=body mass index; CCS=Canadian Cardiovascular Society; CK-MB=creatine kinase-muscle/brain; ICU=intensive care unit; SD=standard deviation
Fig. 1Vasodilatation of potassium chloride (KCl) precontracted radial artery segments induced by papaverine 0.5 mg/ml (n=12) and 2 mg/ml (n=12). Mean±SD. ***P<0.001; SD=standard deviation
Fig. 2Potassium chloride (KCl) and phenylephrine induced contraction of radial artery segments predilated by papaverine 0.5 mg/ml (n=12) and 2 mg/ml (n=12). ***P=0.083.
Fig. 3Representative micrographs showing endothelium (red) of radial artery after treatment with papaverine 0.5 mg/ml (a) and 2 mg/ml (b). Note progressive damage to the endothelial lining. Cell nuclei counterstained by DAPI (blue). Bar = 200 µm.
| Abbreviations, acronyms & symbols | ||||
|---|---|---|---|---|
| PW | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| GL | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| PR | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| JP | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| GPF | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| RK | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| BK | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| KB | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |
| RL | Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published |